- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03659773
Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant Recipients (VaccHemInf)
A Prospective Cohort Study of Efficacy, Safety and Characterization of Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant Recipients
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lyon, France, 69004
- Hôpital de la Croix Rousse
-
Pierre-Bénite, France, 69495
- Centre Hospitalier Lyon Sud
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- allogeneic and autologous HSCT recipients
- ≥ 18 year-old
- patients having been informed of the conditions of the study (24-month follow-up) and having signed the informed consent form
Person with social security insurance
• Additional inclusion criteria for healthy volunteers enrolled (10 volunteers)in the ancillary study of influenza vaccine response:
- health-care workers recruited from the hospital staff
Exclusion Criteria:
- Patient with innate or acquired immune deficiency (severe combined immunodeficiency, Hepatitis C virus (HCV), HBV, HIV infections at any stage)
- Pregnant or breastfeeding women
- History of previous severe allergic reaction to vaccine components
- Patient with no social security coverage, with restricted liberty or under legal protection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: hematopoietic stem cell transplant (HSCT)
immune biomarkers to evaluate vaccine response in HSCT recipients
|
a 38mL-blood sample will be collected before and at 3, 12 and 24 months after complete block vaccination and at 4 weeks after influenza vaccination for the ancillary study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
proportion of responders defined by the increase in specific antibody titers at 3 months after full block vaccination including tetanus, diphtheria, Pneumococcus, Haemophilus influenza type B (Hib), and hepatitis B virus (HBV).
Time Frame: at 3 months after block vaccination
|
ELISA methods will be used to measure serum level concentrations of specific immunoglobulin G (IgG) antibodies to tetanus toxoid, diphtheria toxoid, Hib, pneumococcal capsular polysaccharides and HBV.
For pneumococcus, a 4-fold increase in the IgG titer will be considered significant for immunization.
For Hib, the values between 0.15-1 μg/mL will be significant for immunization (linearity limit of 9 μg/mL).
An IgG titer equal or higher than 0.1 IU/mL for diphtheria and tetanus and higher than 10 mIU/mL for HBV (anti-HBs antibody titer will be considered protective) .
An anti-HBs titer higher than 100 IU/mL will be considered to confer long-lasting protection.
|
at 3 months after block vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
proportion of responders defined by the increase in specific antibody titers at 12 months after full block vaccination including tetanus, diphtheria, Pneumococcus, Haemophilus influenza type B (Hib), and hepatitis B virus (HBV).
Time Frame: at 12 months after block vaccination
|
ELISA methods will be used to measure serum level concentrations of specific IgG antibodies to tetanus toxoid, diphtheria toxoid, Hib, pneumococcal capsular polysaccharides and HBV.
For pneumococcus, a 4-fold increase in the IgG titer will be considered significant for immunization.
For the Hib, the values between 0.15-1 μg/mL will be significant for immunization (linearity limit of 9 μg/mL).
An IgG titer equal or higher than 0.1 IU/mL for diphtheria and tetanus and higher than 10 mIU/mL for HBV (anti-HBs antibody titer) will be considered protective.
An anti-HBs titer higher than 100 IU/mL will be considered to confer long-lasting protection
|
at 12 months after block vaccination
|
proportion of responders defined by the increase in specific antibody titers at 24 months after full block vaccination including tetanus, diphtheria, Pneumococcus, Haemophilus influenza type B (Hib), and hepatitis B virus (HBV).
Time Frame: at 24 months after block vaccination
|
ELISA methods will be used to measure serum level concentrations of specific IgG antibodies to tetanus toxoid, diphtheria toxoid, Hib, pneumococcal capsular polysaccharides and HBV.
For pneumococcus, a 4-fold increase in the IgG titer will be considered significant for immunization.
For the Hib, the values between 0.15-1 μg/mL will be significant for immunization (linearity limit of 9 μg/mL).
An IgG titer equal or higher than 0.1 IU/mL for diphtheria and tetanus and higher than 10 mIU/mL for HBV (anti-HBs antibody titer) will be considered protective.
An anti-HBs titer higher than 100 IU/mL will be considered to confer long-lasting protection
|
at 24 months after block vaccination
|
Correlation between quantification of relevant immune cells of HSCT recipients and vaccine response
Time Frame: at 3, 12 and 24 months after full block vaccination
|
the association between blood T- B- and NK cell counts and subtypes of T and B cells (cells /mm3 of whole blood) and vaccine response will be analyzed
|
at 3, 12 and 24 months after full block vaccination
|
Correlation between proliferative T-cell response to mitogens and antigens and vaccine response
Time Frame: before and at 3 months after full block vaccination
|
lymphocyte proliferation in response to ex vivo T cell stimulation (% of proliferating cells among CD3+ T-cells) will be evaluated The values measured will be defined as normal or abnormal, depending on whether they are within reference intervals (RI) derived from an independent set of healthy volunteers (REALISM protocol).
|
before and at 3 months after full block vaccination
|
Correlation between innate immune response after ex vivo whole blood stimulation and vaccine response
Time Frame: before and at 3 months after full block vaccination
|
The production of tumor necrosis factor (TNF) alpha released by blood cells in response to ex vivo stimulation by lipopolysaccharide (in pg/mL) will be measured The values measured will be defined as normal or abnormal, depending on whether they are within reference intervals (RI) derived from an independent set of healthy volunteers (REALISM protocol).
|
before and at 3 months after full block vaccination
|
proportion of HSCT recipients with adverse event after each vaccination including local and general reactions
Time Frame: 21 days after each vaccination
|
local and general reactions will be monitored for 30 min after each vaccination.
Recipients will be given a diary card to record occurrence and severity of specific local reactions at the injection site and specific general reactions for 21 days after each vaccine injection.
|
21 days after each vaccination
|
ancillary study of cellular and humoral response to one dose of tetravalent inactivated influenza vaccine (IIV)
Time Frame: 4 weeks after influenza vaccination.
|
Hemagglutination-inhibition assay (HAI) will be used to measure serum level concentrations of specific antibodies to the four influenza strains included in the vaccine. Immunization will be defined by seroprotective antibody titers ≥ 1:40 and/or seroconversion (4-fold rise in antibody titers). T-cell responses elicited by IIV will be measured ex vivo by interferon-Gamma ELISpot assay and expressed as number of spot-forming-cells. T-cell responses will be correlated to influenza antibody production, as measured by hemagglutination-inhibition assay (HAI). Influenza vaccine response in allo-HSCT recipients will be compared to that observed in Healthy Volunteers. |
4 weeks after influenza vaccination.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Florence ADER, Pr, Hospices Civils de Lyon
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 69HCL17_0769
- 2017-A03230-53 (Other Identifier: ANSM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vaccination
-
University of PennsylvaniaCompletedVaccine Refusal | Vaccination Hesitancy | Human Papillomavirus VaccinationUnited States
-
University of Roma La SapienzaCompletedVaccination Failure | Vaccination Adverse Events | Specific Antibody ResponseItaly
-
National Cancer Institute (NCI)CompletedHPV16 Anitbody Levels Post Vaccination | HPV18 Antibody Levels Post VaccinationUganda
-
Indiana UniversityNational Center for Advancing Translational Sciences (NCATS)Recruiting
-
Columbia UniversitySeattle Children's Hospital; New York Presbyterian Hospital; Agency for Healthcare...Completed
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.; Wuhan Institute of Biological... and other collaboratorsUnknown
-
China National Biotec Group Company LimitedShanghai Municipal Center for Disease Control and PreventionCompleted
-
Johns Hopkins UniversityNational Institute for Biomedical Imaging and Bioengineering (NIBIB); St. Louis... and other collaboratorsCompleted
-
University of North Carolina, Chapel HillEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
University Hospital, RouenCompleted
Clinical Trials on immune biomarkers to evaluate vaccine response in HSCT recipients
-
Azienda Socio Sanitaria Territoriale degli Spedali...Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Istituti Ospitalieri... and other collaboratorsNot yet recruitingSquamous Cell Carcinoma of the Skin
-
University Hospital, ToulouseInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedDelirium | Covid19 | Post-traumatic Stress DisorderFrance
-
University of AlbertaMerck Canada Inc.Not yet recruitingVaccine Response Impaired | Vaccination Failure